{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T05:36:09Z","timestamp":1740116169048,"version":"3.37.3"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Grant-in-Aid for Scientific Research","award":["25461543"],"award-info":[{"award-number":["25461543"]}]},{"name":"Health Labour Sciences Research","award":["H22-Nanji-Ippan-002"],"award-info":[{"award-number":["H22-Nanji-Ippan-002"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","brainanddevelopment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain and Development"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.braindev.2015.07.006","type":"journal-article","created":{"date-parts":[[2015,8,8]],"date-time":"2015-08-08T12:26:37Z","timestamp":1439036797000},"page":"175-180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Chemical chaperone treatment for galactosialidosis: Effect of NOEV on \u03b2-galactosidase activities in fibroblasts"],"prefix":"10.1016","volume":"38","author":[{"given":"Mohammad Arif","family":"Hossain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsumi","family":"Higaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiko","family":"Shinpo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Nanba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Ozono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3374-6709","authenticated-orcid":false,"given":"Norio","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.braindev.2015.07.006_b0005","doi-asserted-by":"crossref","first-page":"4535","DOI":"10.1073\/pnas.79.15.4535","article-title":"Molecular defect in combined beta-galactosidase and neuraminidase deficiency in man","volume":"79","author":"D\u2019Azzo","year":"1982","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.braindev.2015.07.006_b0010","unstructured":"D\u2019Azzo A, Andria G, Bonten E, Annunziata I. The online metabolic and molecular basis of inherited disease (OMMBID). Galactosialidosis. doi:http:\/\/dx.doi.org\/10.1036\/ommbid.183 [Chapter 152]."},{"key":"10.1016\/j.braindev.2015.07.006_b0015","doi-asserted-by":"crossref","first-page":"12143","DOI":"10.1016\/S0021-9258(17)44147-0","article-title":"The relation between human lysosomal \u03b2-galactosidase and its protective protein","volume":"258","author":"Hoogeveen","year":"1983","journal-title":"J Biol Chem"},{"key":"10.1016\/j.braindev.2015.07.006_b0020","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1432-1033.1985.tb08928.x","article-title":"Human placental neuraminidase. Activation, stabilization and association with \u03b2-galactosidase and its \u2018protective\u2019 protein","volume":"149","author":"Verheijen","year":"1985","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.braindev.2015.07.006_b0025","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1172\/JCI116472","article-title":"Protective protein gene mutations in galactosialidosis","volume":"91","author":"Shimmoto","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.braindev.2015.07.006_b0030","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.braindev.2008.01.012","article-title":"A case of galactosialidosis with a homozygous Q49R point mutation","volume":"30","author":"Matsumoto","year":"2008","journal-title":"Brain Dev"},{"key":"10.1016\/j.braindev.2015.07.006_b0035","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S1096-7192(03)00005-2","article-title":"New mutations in two Dutch patients with early infantile galactosialidosis","volume":"78","author":"Groener","year":"2003","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.braindev.2015.07.006_b0040","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1006\/bbrc.1998.8659","article-title":"Protective protein\/cathepsin A loss in cultured cells derived from an early infantile form of galactosialidosis patients homozygous for the A 1184-G transition (Y395C mutation)","volume":"247","author":"Itoh","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.braindev.2015.07.006_b0045","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2183\/pjab.66.217","article-title":"Japanese-type adult galactosialidosis: a unique and common splice junction mutation causing exon skipping in the protective protein\/carboxypeptidase gene","volume":"66","author":"Shimmoto","year":"1990","journal-title":"Proc Jpn Acad B"},{"key":"10.1016\/j.braindev.2015.07.006_b0050","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0092-8674(88)90999-3","article-title":"Expression of cDNA encoding the human \u201cprotective protein\u201d associated with lysosomal beta-galactosidase and neuraminidase: homology to yeast proteases","volume":"54","author":"Galjart","year":"1988","journal-title":"Cell"},{"key":"10.1016\/j.braindev.2015.07.006_b0055","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1002\/j.1460-2075.1991.tb04980.x","article-title":"A mutation in a mild form of galactosialidosis impairs dimerization of the protective protein and renders it unstable","volume":"10","author":"Zhou","year":"1991","journal-title":"EMBO J"},{"key":"10.1016\/j.braindev.2015.07.006_b0060","doi-asserted-by":"crossref","first-page":"14754","DOI":"10.1016\/S0021-9258(18)98751-X","article-title":"Human lysosomal protective protein has cathepsin A-like activity distinct from its protective function","volume":"266","author":"Galjart","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1016\/j.braindev.2015.07.006_b0065","doi-asserted-by":"crossref","first-page":"26441","DOI":"10.1074\/jbc.270.44.26441","article-title":"Lysosomal protective protein\/cathepsin A. Role of the \u201clinker\u201d domain in catalytic activation","volume":"270","author":"Bonten","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.braindev.2015.07.006_b0070","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S0969-2126(01)00260-X","article-title":"Three-dimensional structure of the human \u201cprotective protein\u201d: structure of the precursor form suggests a complex activation mechanism","volume":"3","author":"Rudenko","year":"1995","journal-title":"Structure"},{"key":"10.1016\/j.braindev.2015.07.006_b0075","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1101\/gad.9.21.2623","article-title":"Mouse model for the lysosomal disorder galactosialidosis and correction of the phenotype with over-expressing erythroid precursor cells","volume":"9","author":"Zhou","year":"1995","journal-title":"Genes Dev"},{"key":"10.1016\/j.braindev.2015.07.006_b0080","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/S0968-0896(02)00005-6","article-title":"Chemical modification of the \u03b2-glucocerebrosidase inhibitor N-octyl-b-valienamine: synthesis and biological evaluation of 4-epimeric and 4-O-(\u03b2-d-galactopyranosyl) derivatives","volume":"10","author":"Ogawa","year":"2002","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.braindev.2015.07.006_b0085","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.braindev.2006.02.002","article-title":"Fibroblast screening for chaperone therapy in \u03b2-galactosialidosis","volume":"28","author":"Iwasaki","year":"2006","journal-title":"Brain Dev"},{"key":"10.1016\/j.braindev.2015.07.006_b0090","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/humu.21516","article-title":"Chemical chaperone therapy: chaperone effect on mutant enzyme and cellular pathophysiology in \u03b2-galactosidase deficiency","volume":"32","author":"Higaki","year":"2011","journal-title":"Hum Mutat"},{"key":"10.1016\/j.braindev.2015.07.006_b0095","doi-asserted-by":"crossref","first-page":"15912","DOI":"10.1073\/pnas.2536657100","article-title":"Chemical chaperone therapy for brain pathology in GM1-gangliosidosis","volume":"100","author":"Matsuda","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.braindev.2015.07.006_b0100","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ymgme.2012.02.012","article-title":"Therapeutic chaperone effect of N-octyl 4-epi-\u03b2-valienamine on murine GM1-gangliosidosis","volume":"106","author":"Suzuki","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.braindev.2015.07.006_b0105","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.gene.2013.11.003","article-title":"Late-onset Krabbe disease is predominant in Japan and its mutant precursor protein undergoes more effective processing than the infantile-onset form","volume":"534","author":"Hossain","year":"2014","journal-title":"Gene"},{"key":"10.1016\/j.braindev.2015.07.006_b0110","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J Biol Chem"},{"key":"10.1016\/j.braindev.2015.07.006_b0115","doi-asserted-by":"crossref","unstructured":"Hossain MA, Higaki K, Saito S, Ohno K, Sakuraba H, Nanba E, et al. Chaperone therapy for Krabbe disease: potential for late-onset GALC mutations. J Hum Genet 2015. doi:http:\/\/dx.doi.org\/10.1038\/jhg.2015.61 [Epub ahead of print].","DOI":"10.1038\/jhg.2015.61"},{"key":"10.1016\/j.braindev.2015.07.006_b0120","first-page":"285","article-title":"Clinical and genetic heterogeneity in galactosialidosis","volume":"1","author":"Suzuki","year":"1988","journal-title":"Brain Dysfunct"},{"key":"10.1016\/j.braindev.2015.07.006_b0125","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/(SICI)1096-8628(19960823)64:3<453::AID-AJMG2>3.0.CO;2-Q","article-title":"Early-infantile galactosialidosis: clinical biochemical, and molecular observations in a new patient","volume":"64","author":"Zammarchi","year":"1996","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.braindev.2015.07.006_b0130","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0009-8981(97)00141-1","article-title":"Fetal diagnosis of galactosialidosis (protective protein\/cathepsin A deficiency)","volume":"266","author":"Itoh","year":"1997","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.braindev.2015.07.006_b0135","doi-asserted-by":"crossref","first-page":"9150","DOI":"10.1074\/jbc.M609304200","article-title":"Pyrimethamine as a potential pharmacological chaperone for late onset forms of GM2 gangliosidosis","volume":"282","author":"Maegawa","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.braindev.2015.07.006_b0140","doi-asserted-by":"crossref","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","article-title":"Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease","volume":"284","author":"Maegawa","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.braindev.2015.07.006_b0145","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2183\/pjab.88.18","article-title":"Pharmacological chaperone therapy for Fabry disease","volume":"88","author":"Ishii","year":"2012","journal-title":"Proc Jpn Acad B"},{"key":"10.1016\/j.braindev.2015.07.006_b0150","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.cell.2008.06.037","article-title":"Chemical and biological approaches synergize to ameliorate protein-folding diseases","volume":"134","author":"Mu","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.braindev.2015.07.006_b0155","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0009-8981(88)90059-9","article-title":"A comparative study of the accumulated sialic acid-containing oligosaccharides from cultured human galactosialidosis and sialidosis fibroblasts","volume":"174","author":"van Pelt","year":"1988","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.braindev.2015.07.006_b0160","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1007\/BF01799942","article-title":"A comparative study of sialyloligosaccharides isolated from sialidosis and galactosialidosis urine","volume":"14","author":"van Pelt","year":"1991","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.braindev.2015.07.006_b0165","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0022-510X(90)90098-8","article-title":"Abnormal glycosphingolipid metabolism in the nervous system of galactosialidosis","volume":"97","author":"Yoshino","year":"1990","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.braindev.2015.07.006_b0170","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/ana.410060310","article-title":"Adult type neuronal storage disease with neuraminidase deficiency","volume":"6","author":"Miyatake","year":"1979","journal-title":"Ann Neurol"},{"key":"10.1016\/j.braindev.2015.07.006_b0175","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1021\/ja963036t","article-title":"Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity","volume":"119","author":"Kim","year":"1997","journal-title":"J Am Chem Soc"}],"container-title":["Brain and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760415001370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760415001370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T03:25:51Z","timestamp":1653017151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0387760415001370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0387760415001370"],"URL":"https:\/\/doi.org\/10.1016\/j.braindev.2015.07.006","relation":{},"ISSN":["0387-7604"],"issn-type":[{"type":"print","value":"0387-7604"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemical chaperone treatment for galactosialidosis: Effect of NOEV on \u03b2-galactosidase activities in fibroblasts","name":"articletitle","label":"Article Title"},{"value":"Brain and Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.braindev.2015.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}